Zemprocitinib is an investigational new drug that is be evaluated by Lynk Pharmaceuticals for the treatment of ankylosing spondylitis and rheumatoid arthritis. It is an janus kinase 1 (JAK1) inhibitor.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.